ReviewMolecular metabolism2022
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease.
Review in Molecular metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Association between dynamic abdominal obesity (DAO) and benign prostatic hyperplasia (lower urinary tract symptoms): evidence from the China Health and Retirement Longitudinal Study (CHARLS).World journal of urology · 2026Article
- Drug-disease interactions in inflammation: mechanisms, clinical Impact, and future directions.Inflammopharmacology · 2026Review
- Pioglitazone improves learning and memory in a rat model of cholinergic dysfunction induced by scopolamine, the roles of oxidative stress and neuroinflammation.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches.Frontiers in nutrition · 2025Review
- Therapeutic effects and mechanisms of Fufang Longdan mixture on metabolic syndrome with psoriasis via miR-29a-5p/IGF-1R axis.Frontiers in pharmacology · 2025Article
- Review
- Adipose tissue macrophages secrete small extracellular vesicles that mediate rosiglitazone-induced insulin sensitization.Nature metabolism · 2024Article
- Insulin resistance has closer correlation with the occurrence of metabolic dysfunction associated steatotic liver disease diagnosed by liver biopsy.Frontiers in medicine · 2024Article
- Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor.Therapeutic advances in endocrinology and metabolism · 2024Review
- Biomarkers of glucose homeostasis as mediators of the relationship of body mass index and waist circumference with COVID-19 outcomes among postmenopausal women: The Women's Health Initiative.Clinical nutrition (Edinburgh, Scotland) · 2023Article
- NLRP3 Inflammasome in Atherosclerosis: Putting Out the Fire of Inflammation.Inflammation · 2023Review
- An Egg White-Derived Peptide Enhances Systemic Insulin Sensitivity and Modulates Markers of Non-Alcoholic Fatty Liver Disease in Obese, Insulin Resistant Mice.Metabolites · 2023Article
- Review
- Waist-to-Hip Ratio and Inflammatory Parameters Are Associated with Risk of Non-Alcoholic Fatty Liver Disease in Patients with Morbid Obesity.Biomedicines · 2022Article
- A dominant negative ADIPOQ mutation in a diabetic family with renal disease, hypoadiponectinemia, and hyperceramidemia.NPJ genomic medicine · 2022Article
- Article
- Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.BMC endocrine disorders · 2022Review
- Metabolic Mechanisms Connecting Alzheimer's and Parkinson's Diseases: Potential Avenues for Novel Therapeutic Approaches.Frontiers in molecular biosciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundChronic disease appears connected to obesity. However, evidence suggests that chronic metabolic diseases are more specifically related to adipose dysfunction rather than to body weight itself. SCOPE OF REVIEW: Further study of the first generation "insulin sensitizer" pioglitazone and molecules based on its structure suggests that is possible to decouple body weight from the metabolic dysfunction that drives adverse outcomes. The growing understanding of the mechanism of action of these agents together with advances in the pathophysiology of chronic metabolic disease offers a new approach to treat chronic conditions, such as type 2 diabetes, fatty liver disease, and their common organ and vascular sequelae. MAJOR
conclusionsWe hypothesize that treating adipocyte dysfunction with new insulin sensitizers might significantly impact the interface of infectious disease and chronic metabolic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.